ENTIA BIOSCIENCES (ERGO)

0.01
OTC Markets
Prev Close 0.01
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.01 / 0.04
Exchange OTC Markets
Shares Outstanding 33.66B
Market Cap 437.60K
Div & Yield N.A. (N.A)

Preliminary Clinical Results For Entia Biosciences, Inc.'s New, Proprietary ErgoD2® Medical Food Show An Average Increase In Kidney Filtration Rate Of Approximately 10% For Over 75% Of Test Subjects, After Only Three Months

ErgoD2 may be an important supplement to existing treatment for individuals suffering from chronic kidney disease (CKD), as an aid in the dietary management of the disease.

Ergomed Increases Its Co-Development Contribution Up To $12,000,000 In CEL-SCI's Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") and its Clinical Research Organization (CRO) Ergomed plc (AIM:ERGO) today announced that they have expanded their co-development agreement with...